Target Name: LOC105376107
NCBI ID: G105376107
Other Name(s): LOC105376107 variant X2 | Uncharacterized LOC105376107, transcript variant X2 | uncharacterized LOC105376107

Exploring the Potential Drug Target and Biomarker LOC105376107 (LOC105376107 variant X2)

LOC105376107 (LOC105376107 variant X2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle, which plays a crucial role in the development and progression of cancer. LOC105376107 (LOC105376107 variant X2) has been shown to promote the growth and survival of various cancer cell lines, including human breast, ovarian, and colorectal cancer. The potential drug target and biomarker properties of LOC105376107 (LOC105376107 variant X2) make it an attractive target for cancer researchers and drug developers.

Potential Drug Target

LOC105376107 (LOC105376107 variant X2) is a key regulator of the cell cycle, and its functions in the cell cycle include the control of mitosis, G1/S transition, and G0/G1 transition. It has been shown to promote the growth and survival of various cancer cell lines, including human breast, ovarian, and colorectal cancer. LOC105376107 (LOC105376107 variant X2) can also inhibit the apoptosis, which is the process of natural cell death. This may contribute to its potential as a drug target.

Biomarker

LOC105376107 (LOC105376107 variant X2) has also been identified as a potential biomarker for cancer. Its expression has been shown to be associated with the outcomes of various cancer clinical trials, including breast, ovarian, and colorectal cancer. LOC105376107 (LOC105376107 variant X2) has also been shown to have a correlation with the survival rate of cancer patients. These findings suggest that LOC105376107 (LOC105376107 variant X2) may be a useful biomarker for cancer diagnosis and treatment.

Conclusion

LOC105376107 (LOC105376107 variant X2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its functions in the cell cycle, including the control of mitosis, G1/S transition, and G0/G1 transition, make it an attractive target for cancer researchers and drug developers. Its potential as a drug target and biomarker make it a promising candidate for cancer treatment. Further research is needed to fully understand the effects of LOC105376107 (LOC105376107 variant X2) on cancer cells and its potential as a drug.

Protein Name: Uncharacterized LOC105376107

More Common Targets

LOC105376110 | LOC105376136 | LOC105376139 | LOC105376156 | LOC105376157 | LOC105376158 | LOC105376161 | LOC105376169 | LOC105376171 | LOC105376177 | LOC105376187 | LOC105376193 | LOC105376196 | LOC105376205 | LOC105376206 | LOC105376208 | LOC105376211 | LOC105376214 | LOC105376219 | LOC105376223 | LOC105376225 | LOC105376234 | LOC105376244 | LOC105376247 | LOC105376250 | LOC105376253 | LOC105376270 | LOC105376287 | LOC105376326 | LOC105376344 | LOC105376356 | LOC105376360 | LOC105376361 | LOC105376372 | LOC105376375 | LOC105376387 | LOC105376391 | LOC105376397 | LOC105376400 | LOC105376407 | LOC105376412 | LOC105376413 | LOC105376422 | LOC105376435 | LOC105376440 | LOC105376442 | LOC105376481 | LOC105376482 | LOC105376483 | LOC105376486 | LOC105376502 | LOC105376504 | LOC105376505 | LOC105376512 | LOC105376523 | LOC105376536 | LOC105376548 | LOC105376558 | LOC105376559 | LOC105376566 | LOC105376576 | LOC105376579 | LOC105376583 | LOC105376595 | LOC105376611 | LOC105376622 | LOC105376626 | LOC105376627 | LOC105376645 | LOC105376659 | LOC105376707 | LOC105376732 | LOC105376740 | LOC105376755 | LOC105376767 | LOC105376781 | LOC105376786 | LOC105376805 | LOC105376809 | LOC105376815 | LOC105376817 | LOC105376818 | LOC105376819 | LOC105376823 | LOC105376845 | LOC105376850 | LOC105376885 | LOC105376898 | LOC105376934 | LOC105376981 | LOC105376991 | LOC105377013 | LOC105377016 | LOC105377022 | LOC105377043 | LOC105377046 | LOC105377054 | LOC105377056 | LOC105377095 | LOC105377097